Profusa (PFSA) Sinks into the Bottom‑Quarter Abyss
Profusa, the high‑flying blank‑check vehicle headquartered in New York, has delivered a brutal blow to its shareholders today, tumbling –4.07 % in a single 24‑hour period that ended at 04:00 PM Central Europe on Thursday, 22 October 2026. At a price of USD 1.12 per share, the company’s market‑cap has collapsed to USD 536 k, a stark contrast to its all‑time high of USD 3 000 recorded on 29 October 2025. The current trading volume—USD 183.5 k in the last day—underscores how thinly the equity is being sold into the void.
The Numbers That Matter
| Metric | Value | Commentary |
|---|---|---|
| Current price | USD 1.12 | A modest figure that belies the company’s historic volatility |
| Supply | 602.2 k shares | Still a small pool, amplifying the price impact of each trade |
| Market cap | USD 536 k | A meager figure for a company that once flirted with USD 3 000 |
| 24‑h trading value | USD 183.5 k | Indicates limited liquidity and a fragile investor base |
| 200‑day SMA | USD 119.31 | The stock is trading far below its long‑term trendline, a red flag for momentum traders |
| 52‑wk high | USD 3 000 | A peak that seems increasingly far‑fetched |
| 52‑wk low | USD 0.7 | A recent trough that still sits above the current price, highlighting the stock’s persistent underperformance |
Profusa’s decline of –60.88 % since the end of last month is not merely a statistical anomaly; it is a harbinger of deeper systemic issues within the blank‑check model. The company’s board, led by the enigmatic NorthView Acquisition Corporation, appears to have failed at its core mandate of identifying and acquiring a valuable target. Instead, the firm’s equity has become a speculative playground for short‑term traders seeking quick gains from volatility.
Why the Market Is Ignoring Profusa
- Lack of a Viable Acquisition Target: NorthView Acquisition Corporation has yet to present a credible acquisition that justifies its valuation. Without a tangible asset, the stock is essentially a speculative bet on a future deal that may never materialize.
- Thin Trading Volume: With only USD 183.5 k of daily trade, liquidity is sparse. Small trades can disproportionately influence the price, leading to exaggerated swings that do not reflect underlying fundamentals.
- High Volatility Relative to Peers: Compared with peer companies such as Arcadia Biosciences (USD 0.15) and Leslie’s (USD 0.06), Profusa’s price volatility is a sign of market uncertainty and diminished investor confidence.
A Broader Context: Peer Performance
| Stock | Ticker | 24‑h % Change | Current Price | Market Cap | Notable News |
|---|---|---|---|---|---|
| Water Intelligence | WATR.L | +1.89 % | GBX 265 | GBX 60.7 mn | 10 k self‑purchase in treasury, reducing voting base |
| Renalytix | RENX.L | 0 % | GBX 5.75 | GBX 44.3 mn | Secured a U.S. Medicare‑reimbursed kidney test, aligning with national care plans |
| Arcadia Biosciences | RKDA | +3.27 % | USD 0.15 | USD 368.6 k | Steady growth in biotech niche |
| Leslie’s | LESL | +17.74 % | USD 0.06 | USD 581 k | Filing for Chapter 11, delisted from Nasdaq, moving to OTC Pink |
While Water Intelligence and Renalytix demonstrate strategic moves—whether through share repurchases that tighten their capital structure or through securing government‑backed contracts—Profusa’s lack of substantive progress starkly contrasts with these peers’ proactive initiatives. The company’s stagnant performance is a cautionary tale for investors who assume that a blank‑check vehicle is a guaranteed avenue to high returns.
The Bottom Line
Profusa’s current trajectory is a textbook example of how a company can implode when its core purpose—acquiring a valuable target—is not fulfilled. Its stock is now a cautionary emblem of speculative risk, thin liquidity, and an unverified business model. For investors, the message is clear: unless NorthView Acquisition Corporation can deliver a concrete, high‑value acquisition, the share price will likely continue its downward spiral, leaving shareholders with a depreciated asset that bears little resemblance to the initial promise of a lucrative blank‑check vehicle.
